Literature DB >> 27450020

Effect of tranilast in comparison with beclomethasone in chronic murine model of asthma.

Manar A Nader1,2, Nariman Gameil2, Rania R Abdelaziz2, Khaled R Zalata3, Amal Osman4, Mohamed M Zedan4, Nermin Abo-Elkheir3, Abeer Abdalla Elsiddig5, Magdy Zedan4.   

Abstract

AIM OF THE STUDY: The current investigation was taken to scrutinize the action of tranilast on the airway remodeling in chronic asthma in mice.
MATERIALS AND METHODS: Intraperitoneal injection of ovalbumin was applied to mice for sensitization and subsequent inhalation of 1% ovalbumin three times week for 10 weeks for challenge. Beclomethasone or tranilast were given daily for the 10 week challenge period. At the end of the study, lung weight index, total collagen content, bronchoalveolar lavage level of total and differential cell counts, interleukin-13, in addition to lung tissue nitrate/nitrite and transforming growth beta-1 were measured. Also, histological analysis was done.
RESULTS: Asthmatic mice demonstrated apparent fibrotic changes. Significant airway fibrosis was demonstrated by hyperplasia of goblet cells and thickening of airway epithelium, increased content of lung collagen, lung and bronchoalveolar lavage of transforming growth factor beta-1 and interleukin-13 mutually accompanied by reduction in nitrate/nitrite generation.
CONCLUSIONS: Beclomethasone influence on airway remodeling was mediated mainly via suppression of eosinophilic recruitment into the airways and reduction of interleukin-13 cytokine levels. Whereas, tranilast effects on airway remodeling was found to be mainly mediated via its inhibitory effect on transforming growth beta-1. Both beclomethasone and tranilast influence airway remodeling by different degrees and mechanisms.

Entities:  

Keywords:  beclomethasone; chronic asthma; inflammation; remodeling; tranilast

Mesh:

Substances:

Year:  2016        PMID: 27450020     DOI: 10.1080/01902148.2016.1207727

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  2 in total

1.  Tranilast attenuates lipopolysaccharide‑induced lung injury via the CXCR4/JAK2/STAT3 signaling pathway.

Authors:  Yufeng Lou; Zhenrong Huang; Hui Wu; Yun Zhou
Journal:  Mol Med Rep       Date:  2022-05-18       Impact factor: 3.423

2.  Tranilast Treatment Attenuates Cerebral Ischemia-Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF-κB and PPARs.

Authors:  Yue Zhuo; Jun Zhuo
Journal:  Clin Transl Sci       Date:  2018-12-31       Impact factor: 4.689

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.